Pharming Group (NASDAQ:PHAR – Get Free Report) had its target price hoisted by research analysts at Canaccord Genuity Group from $37.00 to $38.00 in a research note issued on Monday,Benzinga reports. The firm currently has a “buy” rating on the stock. Canaccord Genuity Group’s price objective would indicate a potential upside of 286.97% from the company’s current price.
Other equities analysts have also recently issued reports about the stock. Wall Street Zen cut shares of Pharming Group from a “strong-buy” rating to a “hold” rating in a research note on Saturday, May 9th. Zacks Research upgraded Pharming Group from a “strong sell” rating to a “hold” rating in a report on Friday, April 10th. Oppenheimer restated an “outperform” rating on shares of Pharming Group in a report on Thursday. Finally, Weiss Ratings downgraded Pharming Group from a “hold (c-)” rating to a “sell (d)” rating in a research report on Monday, May 11th. Three analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, Pharming Group has an average rating of “Hold” and an average target price of $38.67.
Get Our Latest Stock Report on PHAR
Pharming Group Trading Down 2.6%
Pharming Group (NASDAQ:PHAR – Get Free Report) last posted its quarterly earnings data on Thursday, July 30th. The company reported $0.02 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.06 by ($0.04). The company had revenue of $90.20 million during the quarter, compared to the consensus estimate of $99.52 million. Pharming Group had a net margin of 2.51% and a return on equity of 3.40%. On average, research analysts predict that Pharming Group will post 0.45 EPS for the current fiscal year.
Institutional Trading of Pharming Group
A number of institutional investors and hedge funds have recently made changes to their positions in PHAR. EverSource Wealth Advisors LLC acquired a new position in Pharming Group during the second quarter worth $32,000. SmartHarvest Portfolios LLC purchased a new position in shares of Pharming Group in the fourth quarter valued at approximately $224,000. Millennium Management LLC acquired a new position in Pharming Group in the 4th quarter valued at $360,000. Finally, NewEdge Advisors LLC raised its position in shares of Pharming Group by 11,310.3% in the fourth quarter. NewEdge Advisors LLC now owns 28,868 shares of the company’s stock valued at $510,000 after buying an additional 28,615 shares during the last quarter. 0.03% of the stock is currently owned by hedge funds and other institutional investors.
Pharming Group Company Profile
Pharming Group N.V. is a clinical-stage biopharmaceutical company headquartered in Leiden, the Netherlands, with a primary focus on developing and commercializing innovative protein replacement therapies for patients living with rare diseases. The company employs a proprietary transgenic technology platform designed to produce recombinant human proteins in the milk of transgenic animals, enabling scalable and cost-efficient manufacturing of complex therapeutic proteins.
The company’s lead product, RUCONEST (recombinant human C1 esterase inhibitor), is approved for the treatment of acute hereditary angioedema (HAE) attacks in multiple markets, including the United States and Europe.
Read More
- Five stocks we like better than Pharming Group
- SpaceX’s First Earnings Report Could Decide Whether Shorts or Bulls Have Control
- Why Rare Earth Processing Could Be the Real 2027 Opportunity
- The S&P 493 Are Staging a Comeback—This Value ETF Offers Broad Exposure
- TSMC Insiders Are Buying the Pullback—But Is the Signal as Bullish as It Looks?
Receive News & Ratings for Pharming Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pharming Group and related companies with MarketBeat.com's FREE daily email newsletter.
